Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

MLA

Duvivier, Herbert L., et al. “Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.” Journal of Clinical Oncology, vol. 41, no. 2, Nov. 2023, pp. 5140–50. EBSCOhost, https://doi.org/10.1200/JCO.23.00702.

APA

Duvivier, H. L., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Ahn, E. R., Al Baghdadi, T., Alva, A. S., Dublis, S. A., Cannon, T. L., Calfa, C. J., Li, R., Behl, D., Chiu, V. K., Gold, P. J., Marr, A. S., Mileham, K. F., Powell, S. F., Rodon, J., Thota, R., & Grantham, G. N. (2023). Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. Journal of Clinical Oncology, 41(2), 5140–5150. https://doi.org/10.1200/JCO.23.00702

Chicago

Duvivier, Herbert L., Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene R. Ahn, Tareq Al Baghdadi, Ajjai S. Alva, et al. 2023. “Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.” Journal of Clinical Oncology 41 (2): 5140–50. doi:10.1200/JCO.23.00702.